Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I trial of an intranasal, nanoemulsion-adjuvanted herpes simplex virus-2 vaccine.

Trial Profile

Phase I trial of an intranasal, nanoemulsion-adjuvanted herpes simplex virus-2 vaccine.

Status: Planning
Phase of Trial: Phase I

Latest Information Update: 07 May 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Herpes simplex vaccine (Primary)
  • Indications Herpes simplex virus type 2 infections
  • Focus Adverse reactions
  • Sponsors BlueWillow Biologics
  • Most Recent Events

    • 07 May 2018 According to a BlueWillow Biologics media release, NanoBio Corporation has changed its name to BlueWillow Biologics.
    • 02 May 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top